Medicago: Rise and Fall of a Québec City Vaccine Maker

JB
By
James Bennett - Food, Hotels & City Life Writer
2 Min Read

For about twenty years, a Québec City biotech company called Medicago tried to change how vaccines are made. The method was unusual: instead of growing viral proteins in chicken eggs or mammalian cells, the company introduced genetic instructions into Nicotiana benthamiana plants, a tobacco relative, and harvested virus-like particles from the leaves. The approach worked. In February 2022, Health Canada approved Covifenz, the world’s first plant-based COVID-19 vaccine. Thirteen months later, majority shareholder Mitsubishi Chemical shut the company down.

The origin

Medicago was founded in 1999 by Louis Vézina, a plant biologist who had spent the previous decade researching recombinant protein production at Université Laval alongside colleagues in the agriculture faculty. Early funding came from provincial venture capital, Investissement Québec, and federal research grants through Genome Canada. The company took roughly a decade of patient experimentation to demonstrate the platform could reliably produce candidate vaccines against pandemic influenza strains. By 2010, Medicago had completed a proof-of-concept contract for the US Defense Advanced Research Projects Agency and was building a pilot manufacturing facility at Parc technologique du Québec métropolitain.

The tobacco connection

Philip Morris International acquired a minority stake in 2013, prompting debate across the public-health community about the ethics of tobacco-company investment in vaccine work. The argument that ultimately carried weight inside the company was simple: Philip Morris held both the scale-up capital and, through its affiliates, expertise in agricultural cultivation at industrial volume. Mitsubishi Chemical joined as majority partner soon after, and the two companies funded construction of a full-scale production facility on Boulevard Armand-Paris in Saint-Augustin-de-Desmaures. The plant opened in July 2020 with nominal capacity for roughly eighty million doses annually, a scale almost nothing else in the city’s industrial history had matched.

Covifenz and its moment

Clinical trials during the pandemic showed Covifenz delivered roughly 71 percent efficacy against symptomatic COVID-19 in a Phase 3 study with 24,000 participants. Health Canada authorised the vaccine for adults aged 18 to 64 in February 2022. Then the problem became political rather than scientific. The World Health Organization declined to prequalify the vaccine, citing its long-standing policy against endorsing products from companies with any tobacco-industry ownership, whether direct or through minority shareholding. Without prequalification, Canada’s federal procurement agency could not include Covifenz in its international donations through the COVAX initiative, and domestic demand had already moved to mRNA products.

The shutdown

In February 2023, Mitsubishi Chemical announced it was winding down Medicago. The reasons cited were commercial rather than technical. The COVID-19 vaccine market had consolidated around mRNA platforms, the pandemic emergency had passed, and the company had not yet brought its pandemic influenza candidate to late-stage trials. Roughly six hundred employees lost their positions, most of them scientists and technicians concentrated in the Québec City facility and the greenhouses at Saint-Augustin-de-Desmaures. The federal government, which had committed 173 million dollars to the project in 2020, wrote off most of the investment.

What the city kept

The story is not pure loss, despite the headlines of spring 2023 suggesting otherwise. Medicago trained a generation of Québec City biotechnologists in plant-based manufacturing, a specialised skill set that has since dispersed into the university labs, into the CHU de Québec research centre, and into several smaller startups in the regional biotech cluster. The Parc technologique campus, once quieter after the shutdown, now houses follow-on ventures in cell-free protein synthesis and antibody production using some of the same lab space. Louis Vézina himself retired shortly before the shutdown was announced and has since lectured at Université Laval on the platform’s scientific legacy, arguing the underlying biology remains commercially viable under different ownership structures. Whether plant-based vaccine manufacturing will return at scale remains an open question. The technology works. The business case, in a post-pandemic market dominated by a handful of mRNA and protein-subunit producers, proved considerably harder to sustain than anyone at Medicago had predicted in the optimistic spring of 2021.

Share This Article
JB
Food, Hotels & City Life Writer
James shares recommendations for restaurants, accommodations and experiences that capture the energy of Québec City.
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *